PDF icon Download PDF
Dialyse aktuell 2020; 24(09): 355-359
DOI: 10.1055/a-1216-4639
Schwerpunkt
Nephrologie

Blutdruck bei Niereninsuffizienz

Wie niedrig sollte er sein?
Walter Zidek∗
1   Meoclinic, Berlin
› Author Affiliations
› Further Information
Also available ateRef
   Permissions and Reprints
Preview

ZUSAMMENFASSUNG

Die Blutdruckbehandlung bei Niereninsuffizienz hat die beiden Ziele, unabhängig von der Nierenfunktion kardiovaskuläre Ereignisse zu verhindern und das Voranschreiten einer chronischen Niereninsuffizienz zu verlangsamen. Die Datenlage zur Festlegung eines Zielblutdruckwerts ist derzeit nicht befriedigend. Auch unter Berücksichtigung dieser Unsicherheit scheint es derzeit sinnvoll, bei Niereninsuffizienz einen Zielblutdruckwert von unter 130/80 mmHg anzustreben, sowohl bei nichtdiabetischen als auch bei diabetischen Patienten. Bei signifikanter Proteinurie ist möglicherweise auch ein niedrigerer Zielblutdruckwert sinnvoll.



Publication History

Article published online:
12 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Muntner P, Anderson A, Charleston J. et al Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55: 441-451
    CrossrefPubMedSearch in Google Scholar
  • 2 Cha RH, Lee H, Lee JP. et al The Influence of Blood Pressure Patterns on Renal Outcomes in Patients With Chronic Kidney Disease: The Long-Term Follow Up Result of the APrODiTe-2 Study. Medicine (Baltimore) 2020; 99: e19209
    CrossrefPubMedSearch in Google Scholar
  • 3 Whelton PK, Carey RM, Aronow WS. et al 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018; 71: 1269-1324
    CrossrefPubMedSearch in Google Scholar
  • 4 Williams B, Mancia G, Spiering W. et al 2018 ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953-2041
    CrossrefPubMedSearch in Google Scholar
  • 5 The SPRINT Research Group Wright Jr JT, Williamson JD, Whelton PK. et al A randomized trial of intensive versus standard blood-pressure control. New Eng J Med 2015; 373: 2103-2116
    CrossrefPubMedSearch in Google Scholar
  • 6 Malhotra R, Craven T, Ambrosius WT. et al Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. Am J Kidney Dis 2019; 73: 21-30
    CrossrefPubMedSearch in Google Scholar
  • 7 Klahr S, Levey AS, Beck GJ. et al The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
    CrossrefPubMedSearch in Google Scholar
  • 8 Sarnak MJ, Greene T, Wang X. et al The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-351
    CrossrefPubMedSearch in Google Scholar
  • 9 Wright Jr JT, Bakris G, Greene T. et al Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial. JAMA 2002; 288: 2421-2431
    CrossrefPubMedSearch in Google Scholar
  • 10 Appel LJ, Wright Jr JT, Greene T. et al Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
    CrossrefPubMedSearch in Google Scholar
  • 11 Ruggenenti P, Perna A, Loriga G. et al Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-946
    CrossrefPubMedSearch in Google Scholar
  • 12 Bakris GL, Weir MR, Shanifar S. et al Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565
    CrossrefPubMedSearch in Google Scholar
  • 13 Pohl MA, Blumenthal S, Cordonnier DJ. et al Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037
    CrossrefPubMedSearch in Google Scholar
  • 14 Cooper-DeHoff RM, Gong Y, Handberg EM. et al Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-68
    CrossrefPubMedSearch in Google Scholar
  • 15 Patel A. ADVANCE Collaborative Group MacMahon S Chalmers J. et al Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840
    CrossrefPubMedSearch in Google Scholar
  • 16 de Galan BE, Perkovic V, Ninomiya T. et al Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892
    CrossrefPubMedSearch in Google Scholar
  • 17 ACCORD Study Group Cushman WC, Evans GW, Byington RP. et al Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1575-1585
    CrossrefPubMedSearch in Google Scholar